Mike Ufer

2.7k citations

67 papers · 1.9k indexed · h-index 25

Impact in

Internal Medicine top 2%
- Venous Thromboembolism Diagnosis and Management
Pharmacology top 1%
- Pharmacogenetics and Drug Metabolism

Papers in ⓘ

Pharmacology 16
- Pharmacogenetics and Drug Metabolism 15
Molecular Biology 13
- Sphingolipid Metabolism and Signaling 5

Co-authors: Jasper Dingemanse (21 shared papers)Anders Rane (6 shared papers)Elin Kimland (3 shared papers)Ingolf Cascorbi (10 shared papers)Sierk Haenisch (6 shared papers)Ulf Bergman (2 shared papers)Bernd Kammerer (6 shared papers)Pierre‐Éric Juif (7 shared papers)
Journals: European Journal of Clinical Pharmacology (6 papers)Clinical and Translational Science (4 papers)Pharmacoepidemiology and Drug Safety (4 papers)Clinical Pharmacokinetics (4 papers)Clinical Pharmacology & Therapeutics (3 papers)
Partner nations: Switzerland Germany Sweden

In The Last Decade

Mike Ufer

66 papers receiving 1.8k citations

Peers

Countries citing papers authored by Mike Ufer

Since Specialization

Citations

This map shows the geographic impact of Mike Ufer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mike Ufer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mike Ufer more than expected).

Fields of papers citing papers by Mike Ufer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mike Ufer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mike Ufer. The network helps show where Mike Ufer may publish in the future.

Co-authors

The 25 scholars most cited alongside Mike Ufer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mike Ufer Line = papers co-authored together Mike Ufer links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 67 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Comparative Pharmacokinetics of Vitamin K Antagonists Clinical Pharmacokinetics ·Mike Ufer	2005	238
2	CYP3A5 Genotype Markedly Influences the Pharmacokinetics of Tacrolimus and Sirolimus in Kidney Transplant Recipients Clinical Pharmacology & Therapeutics ·Lutz Renders, M Frisman, Mike Ufer, Igor Mosyagin, Sierk Haenisch, U. Ott, Amke Caliebe, Michael Dechant, Felix Braun, Ulrich Kunzendorf, Ingolf Cascorbi	2006	107
3	Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development Thrombosis and Haemostasis ·Mike Ufer	2010	94
4	The challenges of clinical trials in fragile X syndrome Psychopharmacology ·Sébastien Jacquemont, Elizabeth Berry‐Kravis, Randi J. Hagerman, Florian von Raison, F. Gasparini, George Apostol, Mike Ufer, Vincent des Portes, Baltazar Gomez‐Mancilla	2013	91
5	Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 −24C>T polymorphism in young and adult patients with epilepsy Pharmacogenetics and Genomics ·Mike Ufer, Igor Mosyagin, Hiltrud Muhle, Thies Jacobsen, Sierk Haenisch, Robert Häsler, Frank Faltraco, Cornelia Remmler, Sarah von Spiczak, Heyo K. Kroemer, Uwe Runge, Rainer Boor, Ulrich Stephani, Ingolf Cascorbi	2009	83
6	Adverse drug reactions and off‐label prescribing for paediatric outpatients: a one‐year survey of spontaneous reports in Sweden Pharmacoepidemiology and Drug Safety ·Mike Ufer, Elin Kimland, Ulf Bergman	2003	62
7	Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction Journal of the American College of Cardiology ·Peter Sinnaeve, Gregor Fahrni, Dan Schelfaut, Alessandro Spirito, Christian Mueller, Jean‐Marie Frenoux, Abdel Hmissi, Corine Bernaud, Mike Ufer, Tiziano Moccetti, Shaul Atar, Marco Valgimigli	2020	57
8	Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers Pharmacogenetics ·Julia Kirchheiner, Mike Ufer, Ev-Charlotte Walter, Bernd Kammerer, Rainer Kahlich, Christian Meisel, Matthias Schwab, Christoph H. Gleiter, Anders Rane, Ivar Roots, J rgen Brockm ller	2003	57
9	Paediatric adverse drug reactions reported in Sweden from 1987 to 2001 Pharmacoepidemiology and Drug Safety ·Elin Kimland, Anders Rane, Mike Ufer, Georgios Panagiotidis	2005	53
10	Identification of cytochromes P 450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro European Journal of Clinical Pharmacology ·Mike Ufer, Jan Olof Svensson, Kristopher W. Krausz, Harry V. Gelboin, Anders Rane, Gunnel Tybring	2004	52
11	Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes European Heart Journal ·Robert F. Storey, Paul A. Gurbel, Jurriën M. ten Berg, Corine Bernaud, George Dangas, Jean‐Marie Frenoux, Diana A. Gorog, Abdel Hmissi, Vijay Kunadian, Stefan James, Jean‐François Tanguay, Henry Tran, Dietmar Trenk, Mike Ufer, Pim van der Harst, Arnoud W.J. van ‘t Hof, Dominick J. Angiolillo	2019	51
12	Pharmacokinetics and Pharmacodynamics of Approved and Investigational P2Y12 Receptor Antagonists Clinical Pharmacokinetics ·Uta Schilling, Jasper Dingemanse, Mike Ufer	2020	44
13	Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy Pharmacogenetics and Genomics ·Mike Ufer, Celina von Stülpnagel, Hiltrud Muhle, Sierk Haenisch, Cornelia Remmler, Amani Majed, Herbert Plischke, Ulrich Stephani, Gerhard Kluger, Ingolf Cascorbi	2011	43
14	Decreased Sigmoidal ABCB1 (P-Glycoprotein) Expression in Ulcerative Colitis is Associated with Disease Activity Pharmacogenomics ·Mike Ufer, Robert Häsler, Gunnar Jacobs, Sierk Haenisch, Sandra Lächelt, Frank Faltraco, Christian Sina, Philip Rosenstiel, Susanna Nikolaus, Stefan Schreiber, Ingolf Cascorbi	2009	41
15	Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apnea SLEEP ·Marie‐Laure Boof, Jasper Dingemanse, Katharina Lederer, Ingo Fietze, Mike Ufer	2020	35
16	Determination of phenprocoumon, warfarin and their monohydroxylated metabolites in human plasma and urine by liquid chromatography–mass spectrometry after solid-phase extraction Journal of Chromatography B ·Mike Ufer, Bernd Kammerer, Julia Kirchheiner, Anders Rane, Jan‐Olof Svensson	2004	33
17	Quantification of cortisol and 6 beta-hydroxycortisol in human urine by LC-MS/MS, and gender-specific evaluation of the metabolic ratio as biomarker of CYP3A activity Journal of Chromatography B ·Ursula Lutz, Nataly Bittner, Mike Ufer, Werner K. Lutz	2009	33
18	Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem SLEEP ·Mike Ufer, Debra Kelsh, Kerri A. Schoedel, Jasper Dingemanse	2021	32
19	Widespread off-label prescribing of topical but not systemic drugs for 350,000 paediatric outpatients in Stockholm European Journal of Clinical Pharmacology ·Mike Ufer, Anders Rane, A.T. Karlsson, Elin Kimland, Ulf Bergman	2003	31
20	Clinical Pharmacology of the Reversible and Potent P2Y₁₂ Receptor Antagonist ACT‐246475 After Single Subcutaneous Administration in Healthy Male Subjects The Journal of Clinical Pharmacology ·Pierre‐Éric Juif, Margaux Boehler, Michael Dobrow, Mike Ufer, Jasper Dingemanse	2018	30

About Mike Ufer

Mike Ufer is a scholar working on Pharmacology, Molecular Biology, Cardiology and Cardiovascular Medicine, Oncology and Pediatrics, Perinatology and Child Health, having authored 67 papers that have together received 1.9k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (15 papers), Drug Transport and Resistance Mechanisms (10 papers), Antiplatelet Therapy and Cardiovascular Diseases (7 papers), Sleep and Wakefulness Research (7 papers), Pharmacological Effects and Toxicity Studies (6 papers), Atrial Fibrillation Management and Outcomes (6 papers), Pharmaceutical studies and practices (5 papers) and Sphingolipid Metabolism and Signaling (5 papers). The work is most often cited by research in Internal Medicine (174 citations), Pharmacology (381 citations), Transplantation (85 citations), Toxicology (79 citations) and Pediatrics, Perinatology and Child Health (399 citations). Mike Ufer has collaborated with scholars based in Switzerland, Germany and Sweden. Frequent co-authors include Jasper Dingemanse, Anders Rane, Elin Kimland, Ingolf Cascorbi, Sierk Haenisch, Ulf Bergman, Bernd Kammerer, Pierre‐Éric Juif, Rainer Kahlich and Julia Kirchheiner. Their work appears in journals such as European Journal of Clinical Pharmacology, Clinical and Translational Science, Pharmacoepidemiology and Drug Safety, Clinical Pharmacokinetics and Clinical Pharmacology & Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact